Wednesday, April 16, 2014

Aurinia to begin lupus nephritis trial in Q2

Aurinia to begin lupus nephritis trial in Q2

April 15, 2014 by · Leave a Comment 

Tweet Fresh from a US$52-million private placement, Aurinia Pharmaceuticals (TSX-V:AUP) hopes to treat its first lupus patient in the next few weeks in a Phase 2b clinical trial with its voclosporin immunosuppressant in combination with CellCept®, the standard of care for treating lupus nephritis (LN), the most severe form of lupus. “We are now well […]

Rivex sale to help Helix grow pipeline

Rivex sale to help Helix grow pipeline

February 12, 2013 by · Leave a Comment 

Tweet The sale of Helix BioPharma’s (TSX, FSE:HBP) Rivex drug distribution division several weeks ago has allowed Helix to complete the first stage of its business strategy and proceed to the next phase by examining options to expand its lead antibody-conjugate drug in multiple cancer indications and advancing its preclinical pipeline. “We’ve stabilized and focused […]

GeneNews plans private placement, consolidation, U.S. listing

GeneNews plans private placement, consolidation, U.S. listing

December 7, 2012 by · Leave a Comment 

Tweet GeneNews (TSX:GEN) is proposing to complete a private placement of up to 66,666,666 new common shares at a price of 9 cents each for total gross proceeds of up to $6-million. Proceeds will be used to accelerate commercialization of the company’s ColonSentry test in the U.S., development and validation of pipeline products, and general […]

GeneNews partner gets New York okay to market ColonSentry

GeneNews partner gets New York okay to market ColonSentry

February 21, 2012 by · Leave a Comment 

http://www.youtube.com/watch?v=0mzb8_cDcEg’]

Tweet GeneNews (TSX:GEN) announced that Enzo Clinical Labs, a division of Enzo BioChem (NYSE:ENZ), has received approval from New York State’s Department of Health to market ColonSentry, a blood-based test to assess an individual’s current risk for colorectal cancer. Enzo has exclusive rights to market the GeneNews ColonSentry test in the states of New York […]

Isotechnika releases shareholder letter

Isotechnika releases shareholder letter

November 1, 2011 by · Leave a Comment 

Tweet In a letter to shareholders issued today, Isotechnika Pharma (TSX:ISA) CEO Dr. Robert Foster explains the company’s decision to move its voclosporin drug into Phase 3 clinical trials for the prevention of kidney transplant rejection.  He outlines the market opportunity, the scientific rationale and the clinical support for the transplantation indication as well as […]

GeneNews holders okay stock consolidation

GeneNews holders okay stock consolidation

October 31, 2011 by · Leave a Comment 

Tweet Shareholders of GeneNews (TSX:GEN) at a special meeting approved a proposed share consolidation of the basis of one post-consolidation common share for every six pre-consolidation common shares. The timing for implementation of the consolidation will be determined by the company’s board of directors, but will be no later than Jan. 31, 2012. “We believe […]

Isotechnika receives positive scientific advice in Europe for voclosporin

Isotechnika receives positive scientific advice in Europe for voclosporin

October 18, 2011 by · Leave a Comment 

Tweet Isotechnika Pharma (TSX:ISA) said it has received positive Scientific Advice from the European Medicines Agency for a proposed Phase 3 clinical trial protocol of its drug, voclosporin, after the agency reviewed the study design and endpoints for the proposed clinical study.   This ensures that no major objections regarding the design of the study or […]

Afexa gets promising results in cholesterol management

Afexa gets promising results in cholesterol management

August 18, 2011 by · Leave a Comment 

Tweet Afexa Life Sciences (TSX:FXA), the maker of COLD-FX, has achieved promising results of a pilot clinical study investigating the effects of a new formulation, Dilexaponan, on cholesterol management. The open label and proof of concept study explored the safety and optimum dosing range for Dilexaponan in 39 patients with elevated total cholesterol levels. Dilexaponan is […]

Cangene taps Sedor as CEO

Cangene taps Sedor as CEO

August 17, 2011 by · Leave a Comment 

Tweet Cangene (TSX:CNJ) has named John Sedor as president and CEO, effective Sept. 12, replacing Dr. John Langstaff, who stepped down last January to pursue personal interests. CFO Michael Graham, who has also been serving as interim president and CEO during the board’s search process, will continue in his role as CFO. Mr. Sedor most […]

Paladin eyes Mexico and Brazil for expansion

Paladin eyes Mexico and Brazil for expansion

August 16, 2011 by · Leave a Comment 

Tweet Pharmaceutical distributor Paladin Labs (TSX:PLB) has set its sights on moving into Mexico and Brazil as it continues its strategy of expanding internationally to complement its growth in Canada. “I would like to be in more geographies, and we’re keenly interested in Mexico and Brazil and looking to do something there,” CEO Jonathan Goodman […]

Next Page »

Google+